Givosiran + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Hepatic Porphyria
Conditions
Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Trial Timeline
Nov 16, 2017 → May 31, 2021
NCT ID
NCT03338816About Givosiran + Placebo
Givosiran + Placebo is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Acute Hepatic Porphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT03338816. Target conditions include Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03338816 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Hepatic Porphyria